XARELTO

Peak

rivaroxaban

NDAORALFOR SUSPENSIONPriority Review
Approved
Dec 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
21

Mechanism of Action

Factor Xa Inhibitors

Pharmacologic Class:

Factor Xa Inhibitor

Clinical Trials (5)

NCT05900388N/ANot Yet Recruiting

A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)

Started Sep 2026
850 enrolled
Venous ThromboembolismChildren Under 2 Years
NCT07142655N/AActive Not Recruiting

An Observational Study to Learn More About the Safety of Rivaroxaban in Participants With Peripheral Arterial Disease Who Had Surgery to Improve Blood Flow to Their Legs

Started Aug 2025
1,500 enrolled
Peripheral Arterial Disease (PAD)
NCT06444178Phase 1Completed

Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants

Started Sep 2024
224 enrolled
Healthy Volunteers
NCT06193863N/AActive Not Recruiting

An Observational Study to Learn More About How Safe Rivaroxaban is And How Well it Works in Children With Congenital Heart Disease Who Had a Heart Surgery Called the Fontan Procedure

Started Jun 2024
61 enrolled
Prevention of Venous ThromboembolismCongenital Heart DiseaseFontan Procedure+1 more
NCT06232551N/ARecruiting

Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism

Started Jun 2024
152,000 enrolled
Venous Thromboembolic DiseasePulmonary Embolism and ThrombosisDeep Vein Thrombosis+1 more